The MRC WIMM is still one of a relatively small number of international institutes in which outstanding medical research is so closely linked with basic science, with the aim of both producing pioneering translational research and training the next generation of scientists.
Many of the major scientific breakthroughs at our Institute have had a strong translational impact. Our scientists have clarified how the HIV virus and the malaria parasite avoid the immune system and have developed vaccines for meningitis. Our work has established the molecular basis of thalassaemia and identified key genes and processes in a variety of human genetic diseases. Our researchers have discovered the mechanism by which cells and tissues can sense and adapt to oxygen levels and how paternal age can have an effect on disease. In addition we have shown how some severe neurological diseases result from immunological disorders that can be radically improved with new therapies. Recently, work from our researchers has led to a new set of national guidelines on leukaemia monitoring for children with Down Syndrome.
The translational impact of our research is also clear from our growing relationship with industrial partners. Half of our Faculty currently have productive relationships with biotech and pharma. Work at the Institute has generated many patents, and a number of start-up companies were founded by our scientists, including OxStem, Avidex (now Immunocore), Orbit Discovery, Oxford Immunotec and Zegami.
Our contribution to science and society is evident in the awards received by the Institute and our academics. Since our foundation we have hosted 15 Fellows of the Royal Society and in 1996 we were awarded the prestigious Queen’s Anniversary Prize for Higher and Further Education by her Majesty the Queen.
We are extremely proud of the way in which our staff and students have gone on to succeed in their careers after leaving the Institute. Many went on to establish complementary research institutes in Oxford and beyond. Some examples include:
|Prof Charles Bangham, Chair of Immunology at Imperial College London|
|Sir John Bell FRS, Regius Chair of Medicine at the University of Oxford|
|Prof Roy Bicknell, Professor of Functional Genomics at the University of Birmingham|
|Dr Paul Crocker, Professor of Glycoimmunology at the University of Dundee|
|Dame Kay Davies FRS, Professor of Anatomy at the University of Oxford|
|Prof Jeremy Farrar FRS, Director of the Wellcome Trust|
|Prof Jonathan Frampton, Professor of Stem Cell Biology at the University of Birmingham|
|Prof Frances Gotch, Emeritus Profess of Immunology at Imperial College London|
|Prof Ann Harris, Professor of Paediatrics at Northwestern University|
|Prof Chris Higgins, former Vice Chancellor of Durham University|
|Prof Adrian Hill, Director of the Jenner Institute at the University of Oxford|
|Prof Anthony Monaco, neuroscientist and President of Tufts University|
|Prof Paul Moss, Professor of Haematology at the University of Birmingham|
|Sir Peter Ratcliffe FRS, Professor of Clinical Medicine at the University of Oxford|
|Prof Gavin Screaton, Head of the Medical Sciences Division at the University of Oxford|
|Dr Swee Lay Thein, Chief of the Sickle Cell Branch of the National Heart, Lung, and Blood Institute, NIH|